John Higgins Purchases 41,038 Shares of OmniAb (NASDAQ:OABI) Stock

OmniAb, Inc. (NASDAQ:OABI) Director John Higgins purchased 41,038 shares of the stock in a transaction dated Friday, November 7th. The stock was acquired at an average cost of $1.38 per share, for a total transaction of $56,632.44. Following the transaction, the director owned 2,929,148 shares of the company’s stock, valued at approximately $4,042,224.24. This trade represents a 1.42% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

OmniAb Trading Up 1.9%

Shares of OmniAb stock opened at $1.41 on Monday. The firm has a market capitalization of $202.41 million, a PE ratio of -2.44 and a beta of 0.15. OmniAb, Inc. has a 12 month low of $1.22 and a 12 month high of $4.61. The business’s 50-day moving average price is $1.60 and its 200-day moving average price is $1.69.

OmniAb (NASDAQ:OABI) last posted its earnings results on Tuesday, November 4th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. OmniAb had a negative net margin of 301.83% and a negative return on equity of 23.14%. The company had revenue of $2.24 million during the quarter, compared to analyst estimates of $5.64 million. OmniAb has set its FY 2025 guidance at EPS. As a group, analysts predict that OmniAb, Inc. will post -0.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on OABI shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of OmniAb in a research note on Tuesday, October 14th. Royal Bank Of Canada decreased their price target on shares of OmniAb from $4.00 to $3.00 and set an “outperform” rating for the company in a research note on Thursday, August 7th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, OmniAb currently has an average rating of “Moderate Buy” and a consensus target price of $6.67.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of OABI. Isthmus Partners LLC increased its holdings in OmniAb by 17.8% in the 3rd quarter. Isthmus Partners LLC now owns 669,071 shares of the company’s stock valued at $1,071,000 after purchasing an additional 101,028 shares during the last quarter. GSA Capital Partners LLP increased its position in shares of OmniAb by 902.4% in the 3rd quarter. GSA Capital Partners LLP now owns 262,371 shares of the company’s stock valued at $420,000 after purchasing an additional 236,197 shares during the last quarter. Corient Private Wealth LLC purchased a new position in OmniAb in the second quarter valued at approximately $53,000. Osaic Holdings Inc. boosted its holdings in shares of OmniAb by 214.4% in the 2nd quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock valued at $25,000 after buying an additional 9,716 shares in the last quarter. Finally, Bridgeway Capital Management LLC purchased a new stake in OmniAb in the second quarter valued at $94,000. 72.08% of the stock is currently owned by hedge funds and other institutional investors.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.